PH12017501879A1 - Methods for treating cancer - Google Patents

Methods for treating cancer

Info

Publication number
PH12017501879A1
PH12017501879A1 PH12017501879A PH12017501879A PH12017501879A1 PH 12017501879 A1 PH12017501879 A1 PH 12017501879A1 PH 12017501879 A PH12017501879 A PH 12017501879A PH 12017501879 A PH12017501879 A PH 12017501879A PH 12017501879 A1 PH12017501879 A1 PH 12017501879A1
Authority
PH
Philippines
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
PH12017501879A
Other languages
English (en)
Inventor
Chiang J Li
Wei Li
Youzhi Li
Matthew J Hitron
Yuan Gao
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of PH12017501879A1 publication Critical patent/PH12017501879A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12017501879A 2015-04-17 2017-10-18 Methods for treating cancer PH12017501879A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
PH12017501879A1 true PH12017501879A1 (en) 2018-03-05

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501879A PH12017501879A1 (en) 2015-04-17 2017-10-18 Methods for treating cancer

Country Status (16)

Country Link
US (1) US20180085341A1 (OSRAM)
EP (1) EP3283069A1 (OSRAM)
JP (1) JP2018511643A (OSRAM)
KR (1) KR20180006918A (OSRAM)
CN (1) CN107666906A (OSRAM)
AU (1) AU2016247319A1 (OSRAM)
BR (1) BR112017022281A2 (OSRAM)
CA (1) CA2983010A1 (OSRAM)
EA (1) EA201792287A1 (OSRAM)
HK (1) HK1250944A1 (OSRAM)
IL (1) IL255022A0 (OSRAM)
MX (1) MX2017013360A (OSRAM)
PH (1) PH12017501879A1 (OSRAM)
SG (2) SG10201900564WA (OSRAM)
TW (1) TW201713327A (OSRAM)
WO (1) WO2016168856A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688840B2 (ja) 2007-09-10 2015-03-25 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
CA3011800A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2019050924A1 (en) * 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
US12257227B2 (en) * 2018-10-12 2025-03-25 1Globe Biomedical Co., Ltd. Combination solution for treating chemotherapy refractory cancer
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
US20220170940A1 (en) * 2019-03-27 2022-06-02 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688840B2 (ja) 2007-09-10 2015-03-25 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
WO2011116398A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
LT2547205T (lt) 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
CA3011800A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US20180085341A1 (en) 2018-03-29
TW201713327A (zh) 2017-04-16
HK1250944A1 (zh) 2019-01-18
MX2017013360A (es) 2018-08-01
SG11201708504XA (en) 2017-11-29
IL255022A0 (en) 2017-12-31
SG10201900564WA (en) 2019-02-27
EA201792287A1 (ru) 2018-03-30
EP3283069A1 (en) 2018-02-21
WO2016168856A1 (en) 2016-10-20
CN107666906A (zh) 2018-02-06
CA2983010A1 (en) 2016-10-20
KR20180006918A (ko) 2018-01-19
JP2018511643A (ja) 2018-04-26
AU2016247319A1 (en) 2017-11-02
BR112017022281A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
PH12017501879A1 (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EP4302835A3 (en) Methods of treating ovarian cancer
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX379270B (es) Composiciones que comprenden cepas bacterianas.
IL253979B (en) Methods, preparations and kits for cancer treatment
HK1258098A1 (zh) 治疗癌症的方法
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2021006326A (es) Inhibidores de pcna.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009663A (es) Derivados de icariina.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12017501880A1 (en) Methods for treating cancer
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2015013021A (es) 5-bromo-indirrubinas.
MX390571B (es) Metodos para tratamiento de cancer de ovario.
ZA201808381B (en) Methods and compositions for treating advanced stage non-small cell lung cancer
EA201992557A1 (ru) Противоопухолевые соединения
EA201892712A1 (ru) Способы лечения рака яичника
AU2016902922A0 (en) Methods of Treating Cancer (I)